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1627Current guideline recommendations for the management
of patients with stable CAD involve intensive risk factor
management and anti-ischemic therapies, with revasculari-
zation reserved for individuals whose symptoms persist or
progress despite intensive medical therapy (2). Despite these
recommendations, many patients undergo revascularization,
often because of emotional or psychological factors on the
part of both patients and physicians (3,4). More than
1 million percutaneous coronary interventions (PCIs) are
performed annually in the United States (1). Although
estimates vary, it appears that at least one-half of all PCIs in
the United States are performed electively (5).
See page 1634
The COURAGE (Clinical Outcomes Utilizing Revascu-
larization and Aggressive Drug Evaluation) trial recently
demonstrated that, compared with a strategy of PCI plus
optimal medical therapy, an initial strategy of optimal med-
ical therapy alone, with PCI reserved for those with refractory
angina, had similar rates of death or nonfatal myocardial
infarction in individuals with stable CAD who had under-
gone coronary angiography before randomization (6). Also,
over a median follow-up of 4.6 years, only 33% of individuals
randomized to the optimal medical therapy group required
revascularization (6), suggesting that two-thirds of in-
dividuals with stable CAD could potentially avoid PCI dur-
ing this time period if treated initially with optimal medical
therapy alone (7).
Because clinical trial populations tend to be more
adherent and health conscious, it is not clear to what extent
individuals with stable CAD in the United States achieve
the risk factor goals used in the COURAGE trial. There-
fore, using data on participants who reported a history of
CAD at baseline in the national REGARDS (REasons for
Geographic and Racial Differences in Stroke) study, we
sought to examine the proportion of individuals with risk
factor levels similar to the goals used in the COURAGE
trial. Additionally, we examined sociodemographic factors
associated with being at these risk factor goals.
Methods
The REGARDS study was described in detail previously (8).
Brieﬂy, the REGARDS study is a cohort of 30,239
community-dwelling individuals recruited between 2003 and
2007. Although the cohort is currently being followed
longitudinally, this analysis uses data that were collected
during the baseline examination. The cohort was designed to
be balanced on race (white andAfricanAmerican) and sex; the
ﬁnal sample was 42% African Americans and 55% female.
Because the primary goal of the REGARDS study is to
elucidate regional and racial differences in stroke, residents of
the Stroke Belt, located in the southeastern United States,
were oversampled such that 20% of the overall cohort wasselected from the “buckle” of the
Stroke Belt (the coastal plain re-
gion of North Carolina, South
Carolina, and Georgia), 30% from
the rest of the Stroke Belt (the
remaining parts ofNorthCarolina,
South Carolina, and Georgia plus
Alabama, Mississippi, Louisiana,
Arkansas, and Tennessee), and
50% from the remaining 40 con-
tiguous states. Individuals were
identiﬁed by commercially avail-
able lists and contacted by mail
and telephone. Of those deter-
mined to be eligible, 49% agreed
to paricipate. Upon enrollment, participants underwent
a computer-assisted telephone interview followed by an
in-home examination. During the telephone interview,
demographic and self-reported medical information was
obtained. During the in-home examination, the participant’s
blood pressure, height, and weight were measured, and blood
and urine samples were collected.
At enrollment, there were a total of 4,245 participants
who reported a history of CAD, deﬁned as a self-reported
history of myocardial infarction, PCI, or coronary artery
bypass graft surgery. Of these participants, 454 with missing
data on blood pressure, glucose or lipid values, smoking
status, height, weight, or physical activity were excluded.
Additionally, 624 individuals who had not fasted for their
blood draw were excluded from the primary analysis. This
resulted in a ﬁnal sample size for our primary analyses of
3,167 participants with a self-reported history of prevalent
CAD. Individuals excluded from our primary analyses
were more likely to be African American (39% vs. 33%,
p < 0.001) and less likely to live in the Stroke Buckle (17%
vs. 23%, p < 0.001) than those included. Female sex did not
differ signiﬁcantly between those excluded (38%) and those
included (35%) (p ¼ 0.16). We conducted additional sec-
ondary analyses as described in the following without
excluding the 624 individuals who had not fasted for their
blood draw (n ¼ 3,791 for these analyses).
Risk factor treatment goals. The risk factor goals used
for this analysis were based on those used at the beginning
of the COURAGE trial (9,10) and are listed in Table 1.
These goals were based on the American College of Cardi-
ology (ACC) and AHA guidelines at the time that the
COURAGE trial was designed (9,10) and do not vary
signiﬁcantly from current guideline recommendations (2,11)
or the AHA 2020 goals for ideal cardiovascular health (12),
as shown in Table 1. Because our intent was to estimate the
degree to which optimal risk factor levels are achieved in the
general U.S. population in individuals with stable CAD, for
our primary analyses, we deﬁned the blood pressure goal as
achieving both the systolic and diastolic blood pressure goals,
the lipid goal as achieving all 3 lipid goals, and an optimal
body mass index as <25 kg/m2. Exercise was deﬁned as
Table 1
Comparison of Risk Factor Goals Evaluated in the 3,167 Participants With a Self-Reported History of Coronary Heart
Disease at Baseline in the REGARDS Study, 2003–2007
Our Analysis
2012 Stable Ischemic Heart
Disease Guideline (2)
2011 ACCF/AHA/AMA-PCPI
Performance Measures (11)
AHA 2020 Goals for
Ideal Cardiovascular Health (12)
Aspirin use Aspirin use recommended Aspirin use recommended Aspirin use recommended Not addressed
Blood pressure SBP <130 mm Hg and
DBP <85 mm Hg
(<80 mm Hg if diabetic)
SBP <140 mm Hg and
DBP <90 mm Hg
SBP <140 mm Hg and
DBP <90 mm Hg
or 2 agents
SBP <120 mm Hg and
DBP <80 mm Hg
Lipids LDL-C <85 mg/dl,
HDL-C >39 mg/dl, and
triglycerides <150 mg/dl
Moderate or high-dose
statin therapy
LDL-C <100 mg/dl or
statin therapy
Total cholesterol <200 mg/dl
Glucose Fasting glucose <126 mg/dl No class I recommended target Not addressed Fasting glucose <100 mg/dl
Smoking status Nonsmoking status Nonsmoking status Nonsmoking status or received
cessation counseling
Nonsmoking status
Weight BMI <25 kg/m2 BMI <25 kg/m2 Not addressed BMI <25 kg/m2
Physical activity Exercise 4 days/week Exercise 30–60 min at a
minimum of 5 days/week
Not addressed 150 min/week of moderate
intensity
ACCF ¼ American College of Cardiology Foundation; AHA ¼ American Heart Association; AMA ¼ American Medical Association; BMI ¼ body mass index; DBP ¼ diastolic blood pressure; HDL-C ¼ high-density
lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; PCPI ¼ Physician Consortium for Performance Improvement; SBP ¼ systolic blood pressure.
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1628intense physical activity, enough to work up a sweat. Aspirin
use was determined by participant self-report. Because he-
moglobin A1c was not measured in the REGARDS study,
we substituted a fasting glucose of <126 mg/dl in place of a
hemoglobin A1c of <7% (13). Because some of these goals
have higher degrees of evidence to support their use and are
easier to achieve than others, we also examined 3 goals in a
secondary analysis: aspirin use, blood pressure control,
and low-density lipoprotein cholesterol (LDL-C) control
(LDL-C <85 mg/dl).
Sociodemographic variables. Urban residence was deﬁned
based on census tract categories (urban, rural, or mixed).
Functional status was assessed by the physical component
summary score of the Short Form-12 (14). Kidney function
was estimated by the Modiﬁcation of Diet in Renal Disease
equation (15). The presence of depressive symptoms was
deﬁned as a score of 4 on the 4-item version of the Centers
for Epidemiologic Study Depressive Scale (16). Finally,
diabetes was deﬁned as a self-reported history of diabetes, the
use of diabetes medications, a fasting glucose 126 mg/dl,
or a nonfasting glucose 200 mg/dl.
Statistical analyses. We ﬁrst calculated the proportion of
participants in the study sample who met each risk factor
goal listed in Table 1. Then, we calculated a composite score
for each participant reﬂecting the total number of risk factor
goals reached. To determine factors associated with the total
number of goals achieved, we constructed a multivariable
linear regression model, adjusting for age, sex, race, region of
residence, income, education, urban residence, functional
status, kidney function, and depressive symptoms. Similar
methodology was used for the analyses examining meeting
the aspirin, blood pressure, and LDL-C goals.
Additionally, because we required optimal levels of 3 lipid
values to achieve the cholesterol goal, a body mass
index <25 kg/m2, and a fasting glucose of <126 mg/dl in all
participants regardless of their diabetes status in our deﬁni-
tion of optimal risk factor levels, we conducted a series of
secondary analyses in the 3,167 fasting participants. First,to examine control LDL-C alone, we calculated the pro-
portion of individuals who had an LDL-C level <100, <85,
and <70 mg/dl, respectively. Second, we calculated the
number of REGARDS participants with a body mass
index <30 kg/m2. Third, to investigate glucose control in
only those with diabetes, we calculated the proportion of
individuals with diabetes at enrollment who had a fasting
blood sugar <126 mg/dl. Also, because in our primary
analyses, we excluded individuals who were not fasting at the
time their blood was drawn, we calculated the number of
total risk factor goals reached without excluding the 624
individuals who were nonfasting. For this portion of the
analysis, we used a non–high-density lipoprotein cholesterol
(HDL-C) level <100 mg/dl as the lipid criterion for all
participants, and, for those who were nonfasting, we
substituted a glucose level of <200 mg/dl for the glucose
criterion in our deﬁnitions for risk factor goals (Table 1). All
analyses were performed with SAS, version 9.2 (SAS Insti-
tute, Cary, North Carolina). All participants provided
informed consent to participate, and this study was approved
by the institutional review board of each participating
university.
Results
The demographic and clinical characteristics of the study
sample are shown in Table 2. Participants were a mean
69  9 years of age. Approximately one-third was female
and one-third was African American.
The proportion of individuals meeting each risk factor
goal is displayed in Figure 1. Nonsmoking status, fasting
glucose <126 mg/dl, and the regular use of aspirin were the
most frequently met risk factor goals. Overall, 50% of par-
ticipants met the systolic and diastolic blood pressure goals
and 25% participants met the physical activity, body mass
index, or lipid goals. The total number of risk factor goals
met is displayed in Figure 2. Overall, an average of 3.6  1.2
of the 7 total possible risk factor goals was met, whereas
Table 2
Baseline Characteristics of the 3,167 Participants
With a Self-Reported History of Coronary Heart
Disease in the REGARDS Study, 2003–2007
Age, yrs 69  9
Female 35
African American 33
Region
Stroke Buckle 23
Stroke Belt 34
Non-Stroke Belt 44
Annual income, US$*
<20,000 24
20,000–35,000 31
35,000–75,000 32
>75,000 13
Education
Less than high school 16
High school 29
Some college 27
Completed college 29
Urban group
Rural 21
Mixed 11
Urban 68
Kidney function, eGFR, ml/min/1.73 m2
90 29
60–89 50
30–59 18
15–29 2
<15 1
COURAGE risk factors
SBP, mm Hg 130  18
DBP, mm Hg 75  10
Total cholesterol, mg/dl 174  41
LDL-C, mg/dl 100  34
HDL-C, mg/dl 46  14
Triglycerides, mg/dl 143  94
Fasting glucose, mg/dl 109  38
BMI, kg/m2 29.4  5.8
Diabetes 31
PCS of SF-12 42  11
Depressive symptoms 14
Values are mean  SD or %. *Income data are from the 2,812 participants who did not refuse to
report their income.
eGFR ¼ estimated glomerular ﬁltration rate; PCS ¼ physical component score; SF-12 ¼ Short
Form-12; other abbreviations as in Table 1.
Figure 1
Risk Factor Goal Achievement in REGARDS,
2003 to 2007
Proportion of the 3,167 participants with a self-reported history of coronary heart
disease at baseline in the REGARDS study meeting each of the risk factor goals,
2003 through 2007 (see Table 1 for the deﬁnition of the risk factor goals). The
numbers above the bars represent the percentage achieved. ASA ¼ aspirin ther-
apy; BMI ¼ body mass index; BP ¼ blood pressure; Gluc ¼ glucose; PA ¼ physical
activity; Smok ¼ smoking cessation.
Figure 2
Cumulative Number of Risk Factor Goals Achieved
in REGARDS, 2003 to 2007
Cumulative number of risk factor goals (see Table 1 for the deﬁnition of the risk
factor goals) met in the 3,167 participants with a self-reported history of coronary
heart disease at baseline in the REGARDS study, 2003 through 2007. The
numbers above the bars represent the percentage achieved.
JACC Vol. 63, No. 16, 2014 Brown et al.
April 29, 2014:1626–33 Achievement of Optimal Medical Therapy for CAD
1629the median number of goals met was 4. Nearly all partici-
pants met at least 1 risk factor goal. However, less than one-
fourth met 5 goals, and only 17 of the 3,167 participants
(0.5%) met all 7 goals. After multivariable adjustment,
older age, white race, higher income, more education, and
higher physical functioning were independently associated
with meeting more treatment goals (Table 3). REGARDS
participants enrolled in 2007 met slightly more risk factor
goals (3.8  1.2) than those in previous years (3.5  1.2
in 2003 and 3.6  1.2 in each of years 2004 through 2006,
p < 0.01 for each comparison). When examining only
the aspirin, blood pressure, and LDL-C goals, 91% ofparticipants met at least 1 of these 3 goals, and 16% met all
3 goals. Male sex, white race, increased income, and more
education were independently associated with meeting more
treatment goals after multivariable adjustment (Table 4).
In secondary analyses evaluating LDL-C level as a sepa-
rate goal rather than simply 1 of 3 components of the lipid
goal, 57% of individuals had an LDL-C <100 mg/dl, 38%
had an LDL-C <85 mg/dl, and 18% had an LDL-C
<70 mg/dl. Additionally, 61% of individuals had a body
mass index <30 kg/m2 at enrollment, and 44% of in-
dividuals with diabetes had a fasting glucose <126 mg/dl.
After including individuals who had not fasted, the average
number of risk factors goals met was still 3.6  1.2 with a
Table 3
Factors Associated With Achievement of Risk Factor Goals* in the 3,167 Participants With a Self-Reported History of
Coronary Heart Disease at Baseline in the REGARDS Study, 2003–2007
Univariate Results Multivariable Results Standardized Coefﬁcients
Age, yrs (compared with 75 yrs)
61–74 L0.26 (L0.35 to L0.16) L0.27 (L0.37 to L0.18) 0.11
45–60 L0.41 (L0.53 to L0.29) L0.37 (L0.50 to L0.25) 0.13
Female (compared with male) L0.31 (L0.40 to L0.23) 0.03 (0.12 to 0.07) 0.01
African American (compared with white) L0.55 (L0.64 to L0.46) L0.36 (L0.45 to L0.26) 0.14
Region (compared with non-Belt)
Stroke Belt 0.09 (0.02 to 0.16) 0.04 (0.05 to 0.14) 0.02
Stroke Buckle 0.11 (0.03 to 0.19) 0.08 (0.03 to 0.19) 0.03
Urban group (compared with urban)
Mixed 0.18 (0.05 to 0.32) 0.10 (0.04 to 0.24) 0.03
Rural 0.18 (0.08 to 0.29) 0.08 (0.02 to 0.19) 0.03
Annual income, US$ (compared with <$20,000)
20,000–35,000 0.35 (0.23 to 0.47) 0.15 (0.02 to 0.27) 0.05
35,000–75,000 0.48 (0.37 to 0.60) 0.18 (0.05 to 0.31) 0.07
>75,000 0.70 (0.55 to 0.85) 0.29 (0.12 to 0.46) 0.08
Education (compared with completed college)
Some college L0.23 (L0.34 to L0.12) 0.10 (0.21 to 0.01) 0.04
High school L0.27 (L0.38 to L0.16) L0.12 (L0.23 to 0.00) 0.04
Less than high school L0.53 (L0.66 to L0.40) L0.23 (L0.37 to L0.08) 0.07
Depressive symptoms L0.13 (L0.22 to L0.04) 0.12 (0.24 to 0.01) 0.03
Renal function, eGFR, ml/min/1.73 m2
(compared with eGFR 90)
60–89 0.07 (0.00 to 0.14) 0.00 (0.10 to 0.09) 0.00
30–59 0.07 (0.02 to 0.16) 0.12 (0.25 to 0.01) 0.04
15–29 0.23 (0.45 to 0.00) 0.26 (0.57 to 0.05) 0.03
<15 0.14 (0.45 to 0.17) 0.03 (0.45 to 0.39) 0.00
PCS (per 10 points higher score) 0.24 (0.20 to 0.27) 0.17 (0.13 to 0.21) 0.16
Values are the number of additional treatment goals met after multivariable adjustment (95% conﬁdence interval). For example, African Americans achieved 0.36 fewer treatment goals after multivariable
adjustment compared to whites. Statistically signiﬁcant ﬁndings are shown in bold. Multivariable model r2 is 0.11. *Number of additional treatment goals met after multivariable adjustment.
Abbreviations as in Table 2.
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1630median number of goals met of 4. When evaluating
non–HDL-C as a separate measure, 23% of individuals had
a non–HDL-C <100 mg/dl.
Discussion
In this analysis of community-dwelling individuals with self-
reported CAD, we demonstrate that, on average, 4 of a
possible 7 risk factor goals studied in the COURAGE trial
were met, and <1% of individuals achieved all 7 risk factor
goals. Our results expand on data recently published from
the National Cardiovascular Data Registry that focused on
the intensity of pharmacological management in patients
undergoing elective PCI (17). Although risk factor levels
were not reported, less than one-half of all patients under-
going elective PCI for stable angina were receiving phar-
macological therapy with antiplatelet agents, beta-blockers,
and statins before undergoing PCI both before and after
publication of the COURAGE trial (17).
The achievement of risk factor goals that we observed in
this population-based sample was considerably lower than
what participants in the COURAGE trial achieved (10).
At its conclusion, 96% of COURAGE trial participants
were taking antiplatelet therapy compared with 77% of ourstudy sample who reported regular aspirin use; 66% were
exercising at least 150 min/week compared with 25% of
our study sample who reported exercising 4 days/week;
and approximately 60% reached the blood pressure goal
compared with 50% of our study sample (10). Smoking
rates were similar with 19% of COURAGE participants
smoking at the end of the study compared with 15% of our
study sample (10). This suggests that there is substantial
opportunity to improve the risk factor proﬁles of individuals
with CAD if optimal medical therapy, similar to that used
in the COURAGE trial, were adopted on a wider scale.
The COURAGE trial was not successful in reducing
obesity, as the mean body mass index in the COURAGE
trial increased from 28.8  0.13 kg/m2 to 29.3  0.23 kg/m2
during the course of the study, which was similar to the
mean body mass index (29.4  5.8 kg/m2) present in
REGARDS participants with CAD (10). It is also note-
worthy that in the COURAGE trial, not all participants
achieved the study’s goals either. A recent analysis of risk
factor control among diabetic participants in 3 clinical trials,
including COURAGE, demonstrated that risk factor goal
attainment was poor even in a clinical trial setting (18).
These data suggest that although marked improvement can
be made in risk factor control for U.S. adults with CAD,
Table 4
Factors Associated With Achievement of Aspirin Use, Blood Pressure Control, and Low-Density Lipoprotein Cholesterol Control*
in the 3,259 Participants With a Self-Reported History of Coronary Heart Disease at Baseline in the REGARDS Study, 2003–2007
Univariate Results Multivariable Results Standardized Coefﬁcients
Age, yrs (compared with 75 yrs)
61–74 0.04 (0.03 to 0.11) 0.06 (0.01 to 0.14) 0.04
45–60 0.06 (0.03 to 0.15) 0.11 (0.02 to 0.21) 0.05
Female (compared with male) L0.22 (L0.28 to L0.16) L0.09 (L0.16 to L0.02) 0.05
African American (compared with white) L0.40 (L0.46 to L0.34) L0.34 (L0.41 to L0.27) 0.18
Region (compared with non-Belt)
Stroke Belt 0.07 (0.005 to 0.14) 0.03 (0.04 to 0.10) 0.01
Stroke Buckle 0.11 (0.03 to 0.18) 0.06 (0.02 to 0.14) 0.03
Urban group (compared with urban)
Mixed 0.07 (0.03 to 0.16) 0.04 (0.14 to 0.06) 0.01
Rural 0.10 (0.03 to 0.17) 0.00 (0.08 to 0.08) 0.00
Annual income, US$ (compared with <$20,000)
20,000–35,000 0.17 (0.08 to 0.25) 0.05 (0.03 to 0.14) 0.03
35,000–75,000 0.26 (0.17 to 0.34) 0.06 (0.03 to 0.16) 0.03
>75,000 0.42 (0.31 to 0.53) 0.15 (0.02 to 0.27) 0.06
Education (compared with completed college)
Some college L0.11 (L0.19 to L0.03) 0.06 (0.14 to 0.02) 0.03
High school L0.16 (L0.24 to L0.08) 0.08 (0.17 to 0.00) 0.04
Less than high school L0.33 (L0.43 to L0.24) L0.17 (L0.27 to L0.06) 0.07
Depressive symptoms L0.13 (L0.22 to L0.05) 0.01 (0.10 to 0.08) 0.00
Renal function, eGFR, ml/min/1.73 m2
(compared with eGFR 90 ml/min/1.73 m2)
60–89 0.07 (0.00 to 0.14) 0.02 (0.05 to 0.09) 0.01
30–59 0.07 (0.01 to 0.16) 0.05 (0.04 to 0.14) 0.02
15–29 0.23 (0.45 to 0.00) 0.13 (0.37 to 0.09) 0.02
<15 0.15 (0.46 to 0.16) 0.00 (0.31 to 0.30) 0.00
PCS (per 10 points higher score) 0.06 (0.03 to 0.08) 0.02 (0.01 to 0.05) 0.02
Values are the number of additional treatment goals met after multivariable adjustment (95% conﬁdence interval). For example, African Americans achieved 0.33 fewer treatment goals after multivariable
adjustment compared to whites. Statistically signiﬁcant ﬁndings are shown in bold. Multivariable model r2 is 0.07. *Number of additional treatment goals met after multivariable adjustment.
Abbreviations as in Table 2.
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1631achieving all of these risk factor goals may be unrealistic for
many people.
Similar to the ﬁndings in the COURAGE trial (9),
multiple previous studies have demonstrated no reduction
in death or myocardial infarction in stable CAD patients
undergoing PCI compared with those medically managed
(19–23). However, these studies all suggest that the fre-
quency and severity of anginal symptoms are reduced
with PCI (19–23). In the COURAGE trial, individuals
randomized to the optimal medical therapy–only arm
received PCI for angina refractory to medical treatment or
objective evidence of worsening ischemia on noninvasive
testing. With this strategy, one-third of individuals required
PCI over a median follow-up of 4.6 years. In the
COURAGE trial, the added cost of PCI was $10,000
without a signiﬁcant increase in life-years or quality-adjusted
life-years gained (24). Furthermore, PCI as an initial man-
agement strategy was associated with a cost of $206,229 per
quality-adjusted life-year gained (24). A recent publication
from 10 institutions in the Northeastern United States
suggests that at least in this consortium, the number of PCIs
performed for stable angina has decreased since the publi-
cation of the COURAGE trial (25). These authors were
unable to determine whether the observed decline in PCIwas related to changes in risk factor modiﬁcation. However,
given the low number of risk factor targets achieved in the
current study, efforts targeted toward improving risk factor
control in CAD patients may result in substantial reductions
in healthcare costs.
Previous studies have examined compliance with sec-
ondary prevention recommendations but were limited to
speciﬁc populations or the examination of a limited number
of risk factors (26–30). Muntner et al. (28) demonstrated
using data from 1999 through 2010 from the National
Health and Nutrition Examination Survey that many high-
risk individuals had not achieved lipid goals. Ho et al. (29)
examined achievement of lipid and blood pressure goals
in Veterans Affairs facilities; only approximately one-half
of patients were at goal LDL-C levels and less than one-
half were at goal blood pressures. In the Duke Databank for
Cardiovascular Disease from 1995 to 2002, Newby et al.
(30) reported on changes in adherence to pharmacological
therapies but not actual risk factor goals. Use of aspirin
therapy in 2002 was 83% in their study (30), similar to
the rate in the REGARDS study. Our study extends these
aforementioned ﬁndings by examining a wide range of risk
factor treatment goals in a large, nationwide, biracial
community-based population.
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patients are not achieving these risk factor goals. Similar to
Newby et al. (30), the African-American race was associated
with achievement of fewer risk factor goals. For age, we
saw varying results based on the analysis performed. In
the analysis looking at simply aspirin use, blood pressure
control, and LDL-C control, younger age was associated
with meeting more targets. However, in our analysis
looking at all 7 targets, including behavioral targets, older age
was associated with meeting more targets, suggesting that
younger individuals with CAD may have better access
to medications but are less likely to reach behavioral goals. In
addition to age and race, we also observed that low income,
less education, and poor functional status were associated
with achievement of fewer risk factor goals. However, our
model of sociodemographic factors explains only a small
amount of the variance in risk factor control. Although
efforts should be concentrated on the vulnerable subgroups
identiﬁed, achievement of risk factor goals was sufﬁciently
low to justify a population-wide effort to identify and treat
high-risk individuals.
We studied the achievement of risk factor goals to draw
conclusions about implications of the COURAGE trial
(6,9). Instead, had we chose to study achievement of the
ACC/AHA secondary prevention guideline goals (2) or
clinical performance measures for the management of pa-
tients with stable CAD (11), we might have found different
results, although the risk factor goals used in the
COURAGE trial are, in most cases, very similar to those
recommended by the ACC/AHA secondary prevention
guidelines (2) as well as clinical performance measures for
stable CAD (11), as shown in Table 1. However, our intent
was not to examine quality of care but rather to estimate how
close the management of more average CAD patients is to
the treatment goals used in the COURAGE trial (6,9).
Additionally, unlike the goals used in the COURAGE trial,
the secondary prevention guidelines and performance mea-
sures have never been prospectively studied. Based on the
results of the COURAGE trial, a large percentage of in-
dividuals with stable CAD whose care is driven by these
treatment goals can avoid PCI with good quality of life and
no increased risk of myocardial infarction or death. As a
result, given the signiﬁcant number of PCIs performed
annually in the United States, we were interested in studying
the proportion of stable CAD patients who may not
currently be achieving risk factor levels similar to those
achieved in the COURAGE trial. The current results sug-
gest that a large proportion of stable African-American and
white adults with CAD in the United States do not achieve
risk factor levels similar to those used in the COURAGE
trial, potentially contributing to more chronic angina,
impaired quality of life, and potentially avoidable PCIs.
Study limitations. First, the REGARDS participants were
enrolled between 2003 and 2007, and the COURAGE trial
was published in 2007. Therefore, we cannot evaluate
whether increases in the proportion of CAD patientsachieving these risk factor goals have occurred since the
COURAGE trial was published. In addition, our mean age
(69 years) is higher than the baseline age in COURAGE
trial (61 years), and our sample included a higher proportion
of African Americans (33% vs. 5%) and women (35% vs.
15%) than the COURAGE trial. However, the baseline
values for the risk factors studied were very similar in our
participants to those of the COURAGE trial participants at
baseline, suggesting that similar improvements in quality of
life and reductions in the need for revascularization could be
achieved with more intensive risk factor modiﬁcation. Last,
as is the case for most epidemiological studies, we relied on
self-report to identify individuals with CAD. Individuals
with undiagnosed CAD or who failed to report a history of
CAD were not included in this analysis.
Conclusions
On average, in the current study of U.S. black and white
adults with a self-reported history of CAD, only one-half of
the 7 possible modiﬁable risk factor goals were met. One
strategy to enhance quality of life and reduce the number of
PCIs performed may be to increase our focus on risk factor
management for stable CAD patients.
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